Get the Stockscreener App
22.98
0.35%
-0.077
Catalyst Pharmaceuticals Inc stock is traded at $22.98, with a volume of 174.51K.
It is down -0.35% in the last 24 hours and up +17.66% over the past month.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
See More
Previous Close:
$23.06
Open:
$23.08
24h Volume:
174.51K
Relative Volume:
0.16
Market Cap:
$2.75B
Revenue:
$460.48M
Net Income/Loss:
$142.80M
P/E Ratio:
19.48
EPS:
1.18
Net Cash Flow:
$221.79M
1W Performance:
+1.86%
1M Performance:
+17.66%
6M Performance:
+41.58%
1Y Performance:
+72.13%
1-Day Range:
$22.90
$23.22
1-Week Range:
$21.69
$23.74
52-Week Range:
$13.12
$24.64
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Name
Catalyst Pharmaceuticals Inc
Sector
Industry
Phone
(305) 529-2522
Address
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
22.98 | 2.75B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.01 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
720.00 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.89 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.58 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.65 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Initiated | Robert W. Baird | Outperform |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Mar-14-24 | Initiated | Citigroup | Buy |
| Mar-07-24 | Initiated | BofA Securities | Buy |
| Dec-21-23 | Initiated | Oppenheimer | Outperform |
| Aug-24-22 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-07-18 | Resumed | Piper Jaffray | Overweight |
| Oct-05-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-26-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Sep-30-14 | Reiterated | ROTH Capital | Buy |
| Sep-16-14 | Reiterated | ROTH Capital | Buy |
| Sep-15-14 | Reiterated | H.C. Wainwright | Buy |
| Oct-21-13 | Reiterated | Aegis Capital | Buy |
| Sep-24-13 | Initiated | Maxim Group | Buy |
| Sep-06-13 | Reiterated | Aegis Capital | Buy |
| Apr-18-13 | Initiated | Aegis Capital | Buy |
| Aug-27-12 | Upgrade | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| Oct-01-09 | Upgrade | Merriman | Sell → Neutral |
| May-29-09 | Downgrade | Hapoalim | Neutral → Underperform |
| May-29-09 | Downgrade | Merriman Curhan Ford | Buy → Sell |
| Dec-15-08 | Initiated | Merriman Curhan Ford | Buy |
| Nov-28-07 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jan-31-07 | Initiated | Stifel Nicolaus | Buy |
| Jan-05-07 | Initiated | First Albany | Buy |
View All
Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News
Spire Wealth Management Increases Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Sees Significant Growth in Short Interest - MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) Now Covered by Robert W. Baird - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Catalyst Pharmaceuticals (NASDAQ:CPRX) Upgraded to Strong-Buy at Baird R W - MarketBeat
Baird Initiates Coverage of Catalyst Pharmaceuticals (CPRX) with Outperform Recommendation - MSN
This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Baird Initiates Coverage on Catalyst Pharmaceuticals With Outperform Rating, $28 Price Target - Marketscreener.com
Beyond The Numbers: 6 Analysts Discuss Catalyst Pharmaceuticals Stock - Benzinga
SG Americas Securities LLC Buys 24,102 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Price Up 5.4%Time to Buy? - MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) Hits New 1-Year HighWhat's Next? - MarketBeat
CPRX: 3 Niche Healthcare Stocks Tackling Rare Diseases - StockNews.com
EMC Capital Management Purchases 12,340 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Nilsine Partners LLC Invests $700,000 in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Moody Aldrich Partners LLC Trims Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Bought by SG Americas Securities LLC - Defense World
Pacer Advisors Inc. Purchases 151,495 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals stock hits all-time high of $24.44 - MSN
Catalyst Pharmaceuticals stock hits all-time high of $24.44 By Investing.com - Investing.com Australia
Is Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock's Recent Performance Being Led By Its Attractive Financial Prospects? - Simply Wall St
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives $32.86 Consensus Target Price from Analysts - Defense World
11,320 Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Acquired by Dakota Wealth Management - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives $32.86 Consensus Target Price from Brokerages - MarketBeat
Charles B. O?Keeffe Decides to Not Stand for Reelection for Board At the 2025 Annual Meeting of Catalyst Pharmaceuticals, Inc - Marketscreener.com
Catalyst Pharmaceuticals board member to retire By Investing.com - Investing.com Canada
(CPRX) Investment Analysis - Stock Traders Daily
Catalyst Pharmaceuticals board member to retire - MSN
Catalyst Pharmaceuticals (CPRX) Stock Price, News & Analysis - MarketBeat
Catalyst Pharma Announces Board Member’s Departure - TipRanks
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock - Yahoo Finance
Catalyst Pharmaceuticals Receives Prestigious Ranking on - GlobeNewswire
FIRDAPSE now available in Japan for muscle weakness - MSN
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan - The Manila Times
Catalyst Pharmaceuticals Posts Corporate Presentation in Recent 8-K Filing - Defense World
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Short Interest Up 12.5% in December - MarketBeat
Redhawk Wealth Advisors Inc. Takes $1.27 Million Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
JPMorgan Chase & Co. Boosts Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Catalyst Pharmaceuticals: The Stars Align For Flagship FIRDAPSE (NASDAQ:CPRX) - Seeking Alpha
Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Price Expected to Rise, HC Wainwright Analyst Says - Defense World
Catalyst Pharmaceuticals Inc Stock (CPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Catalyst Pharmaceuticals Inc Stock (CPRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Miller Steve | Chief Op. & Scientific Officer |
Dec 13 '24 |
Option Exercise |
4.01 |
235,000 |
942,350 |
921,996 |
| Miller Steve | Chief Op. & Scientific Officer |
Dec 10 '24 |
Option Exercise |
4.01 |
50,000 |
200,500 |
736,996 |
| Miller Steve | Chief Op. & Scientific Officer |
Dec 10 '24 |
Sale |
21.93 |
50,000 |
1,096,350 |
686,996 |
| O'Keeffe Charles B | Director |
Dec 10 '24 |
Option Exercise |
4.01 |
40,000 |
160,400 |
727,137 |
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):